Hayden E. Klein

Tom Robinson, vice president of global access at JDRF, talks about how the community and people living with type 1 diabetes (T1D) have contributed to the T1D Index, from development to publication and going forward.

Patrick Reville, MD, MPH, instructor, Department of Leukemia, MD Anderson Cancer Center, discusses findings on an updated treatment regimen for newly-diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.

The study also showed daily energy intake was inversely correlated with estimated glucose disposal rate (eGDR), a marker for insulin resistance (IR).

Leaders from Ochsner, Xavier, and their partners gathered on September 13, 2022, in New Orleans to offer an overview of the Healthy State initiative during a session of the Institute for Value-Based Medicine®.

This new study shows that family medicine physicians in rural areas tend to be less comfortable in HIV pre-exposure prophylaxis (PrEP)-related clinical activities and conversations with adolescents than those in urban areas.

Health care providers must acknowledge unconscious bias and watch for it to make sure treatments are given equitably, said Mary Cushman, MD, professor of medicine at the University of Vermont, director of the thrombosis and hemostasis program at the University of Vermont Medical Center.

The longer follow-up in the primary analysis of TRANSFORM provides confidence in the durability of patient responses to lisocabtagene maraleucel (liso-cel), said Jeremy Abramson, MD, director of the lymphoma program, Massachusetts General Hospital Cancer Center.

Ajai Chari, MD, professor of medicine, director of clinical research, Icahn School of Medicine at Mount Sinai, explains the mechanism of action of talquetamab and what method of delivery patients may prefer.

Third-line ponatinib is the optimal treatment option for patients with chronic myeloid leukemia in chronic phase (CML-CP) without T3151 mutation, said Elias Jabbour, MD, professor of medicine, Department of Leukemia, MD Anderson Cancer Center.

About 10% of patients with blood cancer, especially those with B-cell lymphomas, who did not make anti-spike antibodies after vaccination experienced breakthrough COVID-19 infection, said Lee Greenberger, PhD, chief scientific officer, Leukemia and Lymphoma Society.

Federico Stella, MD, University of Milan, explains why it was important to challenge the idea that the low-microbial protective diet is more beneficial than a nonrestrictive diet in patients with neutropenia.

Building equitable clinical trials means being thoughtful about trial design and criteria, said Matthew J. Maurer, DSc, statistician at Mayo Clinic, director of the statistics and informatics core of the Lymphoma Epidemiology of Outcomes (LEO) cohort.

The field of hemophilia therapy is advancing, with hemostatic rebalancing agents and gene therapy expected over the next year, said Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory.

Tom Robinson, vice president of global access at JDRF, lists 3 pieces of advice for groups looking to create indexes for other conditions similar to the Type 1 Diabetes (T1D) Index.

Due to the study’s small sample, further research is needed to understand the role of bromocriptine in reducing blood pressure and artery stiffness in youth with type 1 diabetes (T1D).

Emma Searle, PhD, consultant hematologist, The Christie Hospital NHS Foundation Trust, touches on key points learnt from MajesTEC-2 data and other data to look forward to at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Neil Iyengar, MD, from Memorial Sloan Kettering Cancer Center, is expecting updates on therapies to fight human epidermal growth factor 2 (HER2)–positive breast cancer and novel antibody drug conjugates at the upcoming San Antonio Breast Cancer Symposium (SABCS).

The first priority isn't limiting the rise in type 1 diabetes (T1D) prevalence, it's limiting the rise of missing prevalence, said Tom Robinson, vice president of global access at JDRF.

A review including nearly 40 million total participants showed a statistically significant positive association between infection with COVID-19 and risk of type 1 or type 2 diabetes.

About 1 in 5000 males are born with hemophilia, according to Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program.

A more-developed version of the assay used in this study may help manage patients with acute decompensation of liver cirrhosis or acute-on-chronic liver failure before liver transplantation.

Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, addresses what health systems need to do to improve HIV therapy accessibility and affordability.

Now that long-acting injectables are approved, the next big concern is patient access, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.

According to the study authors, bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) may be an option for simplification following viral suppression.

Nancy Reau, MD, section chief of hepatology at Rush University Medical Center, elaborates on how to improve provider knowledge on liver disease guidelines.

Updating the Type 1 Diabetes (T1D) Index each year with the latest data and literature and implementing feedback is important for at least the first few years, said Tom Robinson, vice president of global access at JDRF.

Serum bicarbonate level also did not appear to affect the accuracy of real-time continuous glucose monitoring (rtCGM) in pediatric diabetic ketoacidosis (DKA).

Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, talks about how HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline address disparities in patient access and adherence.

Patients with Medicare Advantage (MA) were 1.5 times more likely to die within a month of surgical removal of their stomach or liver, and twice as likely to die within a month of oncologic surgery of the pancreas, compared with patients with traditional Medicare.

As patients come into clinic and receive appropriate follow-up, we can hopefully find ways to mitigate the increase in alcoholic hepatitis, said Nancy Reau, MD, section chief of hepatology at Rush University Medical Center.